DWTX

Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).

Wall Street analysts forecast DWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DWTX is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Dogwood Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Dogwood Therapeutics Inc. EPS for the last quarter amounts to -8.20 USD, decreased -84.03 % YoY.

Dogwood Therapeutics Inc (DWTX) has 12 emplpoyees as of December 15 2025.

Today DWTX has the market capitalization of 202.74M USD.